Suppr超能文献

一线治疗失败:863例复发缓解型多发性硬化症患者队列中的预测因素

First line treatment failure: Predictive factors in a cohort of 863 Relapsing Remitting MS patients.

作者信息

Ayrignac Xavier, Bigaut Kevin, Pelletier Jean, de Seze Jérôme, Demortiere Sarah, Collongues Nicolas, Maarouf Adil, Pinna Frédéric, Aouinti Safa, Carra Dallière Clarisse, Kremer Laurent, Charif Mahmoud, Picot Marie Christine, Labauge Pierre

机构信息

CRC SEP, Montpellier University Hospital, INSERM, Univ Montpellier, Montpellier.

CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France.

出版信息

Mult Scler Relat Disord. 2021 Feb;48:102686. doi: 10.1016/j.msard.2020.102686. Epub 2020 Dec 13.

Abstract

BACKGROUND

The advent of new, potent, disease-modifying therapies has dramatically changed the management of multiple sclerosis (MS). Along with these possibilities, it is crucial to better recognize patients who are at risk of first line treatment (FLT) failure and switch to highly effective therapies (HET).

OBJECTIVES

To identify baseline prognostic factors associated with FLT failure in relapsing remitting MS (RR-MS) patients.

METHODS

We included recently diagnosed RR-MS patients starting an FLT identified from 3 French MS centers databases. Baseline characteristics were included in a multivariable Cox analysis to identify the main factors associated with FLT failure.

RESULTS

Eight hundred sixty-three patients were included. We observed an overall rate of treatment failure of 23.5%. The main baseline characteristics associated with treatment failure were age <26 years at treatment start (HR= 2.1, p<0.001), EDSS ≥2 (HR=2.1, p<0.001) and ≥2relapses in the previous year (HR=1.5, p=0.04). The association with the presence of gadolinium enhancement on MRI was not statistically significant. EDSS progression was only significantly associated with age at treatment start and treatment failure.

CONCLUSION

Our series demonstrates that some clinical and imaging factors are associated with treatment failure, and should be considered when planning treatment strategy in patients with recently diagnosed RR-MS.

摘要

背景

新型强效疾病修正疗法的出现极大地改变了多发性硬化症(MS)的治疗方式。伴随着这些可能性,更好地识别有一线治疗(FLT)失败风险并转而使用高效疗法(HET)的患者至关重要。

目的

确定复发缓解型多发性硬化症(RR-MS)患者中与FLT失败相关的基线预后因素。

方法

我们纳入了从3个法国MS中心数据库中识别出的开始接受FLT治疗的新诊断RR-MS患者。基线特征纳入多变量Cox分析,以确定与FLT失败相关的主要因素。

结果

共纳入863例患者。我们观察到总体治疗失败率为23.5%。与治疗失败相关的主要基线特征为治疗开始时年龄<26岁(HR = 2.1,p<0.001)、扩展残疾状态量表(EDSS)≥2(HR = 2.1,p<0.001)以及前一年复发≥2次(HR = 1.5,p = 0.04)。MRI上钆增强的存在与之的关联无统计学意义。EDSS进展仅与治疗开始时的年龄及治疗失败显著相关。

结论

我们的系列研究表明,一些临床和影像学因素与治疗失败相关,在为新诊断的RR-MS患者制定治疗策略时应予以考虑。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验